4.7 Letter

Low-affinity CAR T cells exhibit reduced trogocytosis, preventing rapid antigen loss, and increasing CAR T cell expansion

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Article Hematology

Interventions and outcomes of adult patients with B-ALL progressing after CD19 chimeric antigen receptor T-cell therapy

Kitsada Wudhikarn et al.

Summary: CD19-targeted CAR T-cell therapy is a breakthrough treatment for relapsed/refractory B-ALL patients, but most adult patients progress after treatment. Although some patients achieve sustained remissions with salvage treatments such as blinatumomab, inotuzumab, and reinfusion of CAR T cells, the overall prognosis remains poor. Novel therapeutic strategies are needed to reduce the risk of progression and improve outcomes for these patients.
Article Oncology

Durable Responses and Low Toxicity After Fast Off-Rate CD19 Chimeric Antigen Receptor-T Therapy in Adults With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia

Claire Roddie et al.

Summary: A novel second-generation CD19-CAR therapy (AUT01) has shown promising results in the treatment of relapsed or refractory adult B-cell acute lymphoblastic leukemia (B-ALL), demonstrating tolerable safety profile, high remission rates, and excellent persistence. This therapy has the potential to become a stand-alone treatment option for r/r adult B-ALL.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Article Multidisciplinary Sciences

CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape

Mohamad Hamieh et al.

NATURE (2019)

Editorial Material Multidisciplinary Sciences

Cells nibble one another via the under-appreciated process of trogocytosis

Amber Dance

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)

Article Biotechnology & Applied Microbiology

Balance of Anti-CD123 Chimeric Antigen Receptor Binding Affinity and Density for the Targeting of Acute Myeloid Leukemia

Silvia Arcangeli et al.

MOLECULAR THERAPY (2017)